Abstract
Positron emission tomography/computed tomography (PET/CT) with Galium-68 prostate-specific membrane antigen (68Ga-PSMA) PET/CT) is a valuable tool for initial staging, recurrence detection, and assessment of treatment response in men with prostate cancer. Metastatic spread to regional and distant lymph nodes, bone, lung and liver is well known and expected in patients with castration-resistant disease. However, the application of a highly sensitive whole-body imaging modality such as 68Ga-PSMA PET/CT can reveal metastatic foci in rare or unusual locations. We present the case of an 82-year-old patient with prostate adenocarcinoma who underwent long-term androgen deprivation therapy. A 68Ga-PSMA PET/CT scan was performed in June 2021 due to significant prostate-specific antigen elevation and revealed disease progression with widespread regional and distant metastases, including a soft-tissue mass in the right breast that demonstrated intense radiotracer uptake; this mass was subsequently resected and histologically confirmed. This case underscores the excellent diagnostic performance of 68Ga-PSMA PET/CT for atypical metastatic sites.
Keywords:
Prostate cancer, breast metastasis, 68Ga-PSMA PET/CT
Ethics
Informed Consent: Informed consent was obtained from the patient for the publication of his anonymized images and relevant clinical information.
Authorship Contributions
Concept: G.G., Design: N.H., V.H., Data Collection or Processing: M.I., N.H., Analysis or Interpretation: P.N., M.I., V.H., Literature Search: P.N., M.I., Writing: G.G.
Conflict of Interest: No conflicts of interest were declared by the authors.
Financial Disclosure: The authors declare that this study has received no financial support.
References
1Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, Cho SY, Fanti S, Giesel FL, Goffin K, Haberkorn U, Jacene H, Koo PJ, Kopka K, Krause BJ, Lindenberg L, Marcus C, Mottaghy FM, Oprea-Lager DE, Osborne JR, Piert M, Rowe SP, Schöder H, Wan S, Wester HJ, Hope TA, Herrmann K. PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023;50:1466-1486.
2Zhang S, Peng W, Cheng L, Pei B, Zhou X, Wang M, Jiang L, Lu C, Xu L. Metastasis of prostate cancer to breast: a case report. Front Oncol. 2025;15:1580441.
3Lima V, Martinez-Lapus FG, Demegillo KJ. Breast metastasis from castrate-resistant prostatic adenocarcinoma mimicking as a second primary: a case report. World J Oncol. 2020;11:37-40.
4Kumar Chauhan P, Jain M, Adiga P, Shivalingaiah M. Breast lump: an uncommon metastasis of prostate cancer. archives of Clinical and Medical Case Reports. 2020;4:624-628.
5Sasikumar A, Joy A, Nair BP, Pillai MRA, Madhavan J. False positive uptake in bilateral gynecomastia on 68Ga-PSMA PET/CT scan. Clin Nucl Med. 2017;42:e412-e414.
6Metwalley KA, Farghaly HS. Gynecomastia in adolescent males: current understanding of its etiology, pathophysiology, diagnosis, and treatment. Ann Pediatr Endocrinol Metab. 2024;29:75-81.
7Polverari G, Ceci F, Calderoni L, Cervati V, Farolfi A, Castellucci P, Fanti S. Male breast cancer detected by 68 Ga-PSMA-11 PET/CT in a patient with prostate cancer with pelvic lymph node metastasis. Clin Genitourin Cancer. 2019;17:154-156.
